These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11814539)

  • 21. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
    Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
    Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
    Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naltrexone augmentation of neuroleptics in schizophrenia.
    Sernyak MJ; Glazer WM; Heninger GR; Charney DS; Woods SW; Petrakis IL; Krystal JH; Price LH
    J Clin Psychopharmacol; 1998 Jun; 18(3):248-51. PubMed ID: 9617985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A new therapeutic approach tp drug-resistant schizophrenia: clozapine. Long-term prospective study in 16 patients].
    Jalenques I; Coudert AJ
    Acta Psychiatr Belg; 1992; 92(6):323-38. PubMed ID: 1364281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early prediction of antipsychotic response in schizophrenia.
    Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM
    Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
    J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
    Lin CH; Chou LS; Lin CH; Hsu CY; Chen YS; Lane HY
    J Clin Psychiatry; 2007 Oct; 68(10):1522-7. PubMed ID: 17960966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
    Ross RG; Novins D; Farley GK; Adler LE
    J Child Adolesc Psychopharmacol; 2003; 13(3):301-9. PubMed ID: 14642018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?
    Meltzer HY; Jayathilake K
    J Clin Psychiatry; 1999; 60 Suppl 10():47-51. PubMed ID: 10340687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
    Breier A; Hamilton SH
    Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome to clozapine treatment in chronic psychiatric inpatients.
    Advokat CD; Bertman LJ; Comaty JE
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Jan; 23(1):1-14. PubMed ID: 10368852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.
    Gunduz-Bruce H; Oliver S; Gueorguieva R; Forselius-Bielen K; D'Souza DC; Zimolo Z; Tek C; Kaliora S; Ray S; Petrides G
    Schizophr Res; 2013 Feb; 143(2-3):344-7. PubMed ID: 23219861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
    Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
    Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.